An optimal scheme to boost immunity and suppress viruses for HIV by combining a phased immunotherapy with the sustaining antiviral therapy

Youyi Yang; Yongzhen Pei; Xiyin Liang; Yunfei Lv; Youyi Yang; Yongzhen Pei; Xiyin Liang; Yunfei Lv

doi:10.3934/mbe.2020253

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 5: 4578-4608. doi: 10.3934/mbe.2020253

Previous Article Next Article

Research article Special Issues

An optimal scheme to boost immunity and suppress viruses for HIV by combining a phased immunotherapy with the sustaining antiviral therapy

School of Mathematical Sciences, Tiangong University, Tianjin 300387, China

Received: 12 April 2020 Accepted: 21 June 2020 Published: 02 July 2020

Despite many approaches to treat HIV virus, the endeavor, due to the inability of therapy to eradicate HIV infection, has been aroused to formulate rational therapeutic strategies to establish sustained immunity to suppress viruses after stopping therapy. In this paper, incorporating the time lag of the expansion of immune cells, we propose an explicit model with continuous antiretroviral therapy (CATT) and an intermittent immunotherapy to describe an interaction of uninfected cells, HIV virus and immune response. Two kinds of bistability and the sensitivities of the amplitude and period of the periodic solution with respect to all of parameters indicate that both ε and b relating to the therapy are scheduled to propose an optimal treatment tactics. Furthermore, taking a patient performed a CATT but with an unsuccessful outcome as a example, we inset a phased immunotherapy into the above CATT and then adjust the therapeutic session as well as the inlaid time to quest the preferable therapeutic regimen. Mathematically, we alter the solution of system from the basin of the attraction of the immune-free equilibrium to the immune control balance when the treatment is ceased, meanwhile minimize the cost function through a period of combined therapy. Due to the particularity of our optimal problem, we contribute a novel optimization approach by meshing a special domain on the antiretroviral and immunotherapy parameters ε and b, to catch an optimal combined treatment scheme. Simulations exhibit that early mediating immunotherapy suppresses the load of virus lower while shortening the combined treatment session does not reduce but magnify the cost function. Our results can provide some insights into the design of optimal therapeutic strategies to boost sustained immunity to quell viruses.
- HIV,
- bistability,
- parametric sensitivity,
- sustained immunity,
- optimal combined treatment
Citation: Youyi Yang, Yongzhen Pei, Xiyin Liang, Yunfei Lv. An optimal scheme to boost immunity and suppress viruses for HIV by combining a phased immunotherapy with the sustaining antiviral therapy[J]. Mathematical Biosciences and Engineering, 2020, 17(5): 4578-4608. doi: 10.3934/mbe.2020253

Related Papers:

Abstract

Despite many approaches to treat HIV virus, the endeavor, due to the inability of therapy to eradicate HIV infection, has been aroused to formulate rational therapeutic strategies to establish sustained immunity to suppress viruses after stopping therapy. In this paper, incorporating the time lag of the expansion of immune cells, we propose an explicit model with continuous antiretroviral therapy (CATT) and an intermittent immunotherapy to describe an interaction of uninfected cells, HIV virus and immune response. Two kinds of bistability and the sensitivities of the amplitude and period of the periodic solution with respect to all of parameters indicate that both ε and b relating to the therapy are scheduled to propose an optimal treatment tactics. Furthermore, taking a patient performed a CATT but with an unsuccessful outcome as a example, we inset a phased immunotherapy into the above CATT and then adjust the therapeutic session as well as the inlaid time to quest the preferable therapeutic regimen. Mathematically, we alter the solution of system from the basin of the attraction of the immune-free equilibrium to the immune control balance when the treatment is ceased, meanwhile minimize the cost function through a period of combined therapy. Due to the particularity of our optimal problem, we contribute a novel optimization approach by meshing a special domain on the antiretroviral and immunotherapy parameters ε and b, to catch an optimal combined treatment scheme. Simulations exhibit that early mediating immunotherapy suppresses the load of virus lower while shortening the combined treatment session does not reduce but magnify the cost function. Our results can provide some insights into the design of optimal therapeutic strategies to boost sustained immunity to quell viruses.

References

[1]	J. Henkel, Attacking AIDS With a 'Cocktail' Therapy, Fda Consum., 33 (1999), 12-17.
[2]	A. S. Perelson, P. W. Nelson, Mathematical Analysis of HIV-1 Dynamics in Vivo, Siam Rev., 41 (1999), 3-44.
[3]	V. D. Martino, T. Thevenot, J. F. Colin, N. Boyer, M. Martinot, F. D. Michele, et al., Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B, Gastroenterology, 123 (2002), 1812-1822.
[4]	D. Lamarre, A. Daniel, C. Paul, M. Bailey, P. Beaulieu, G. Bolger, et al., An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus, Nature, 426 (2003), 186-189.
[5]	E. D. Clercq, Antiviral drugs in current clinical use, J. Clin. Virol., 30 (2004), 0-133.
[6]	A. Bouhnik, M. Preau, E. Vincent, M. P. Carrieri, H. Gallais, G. Gallais, et al., Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy, Antivir. Ther., 10 (2005), 53-61.
[7]	M. Perreau, R. Banga, G. Pantaleo, Targeted Immune Interventions for an HIV-1 Cure, Trends Mol. Med., 23 (2017), 945-961.
[8]	T. Bruel, B. F. Guivel, S. Amraoui, M. Malbec, L. Richard, K. Bourdic, et al., Elimination of HIV-1-infected cells by broadly neutralizing antibodies, Nat. Commun., 7 (2016), 10844.
[9]	M. N. Wykes, S. R. Lewin, Immune checkpoint blockade in infectious diseases, Nat. Rev. Immunol., 18 (2017), 91-104.
[10]	R. M. Ruprecht, Anti-HIV Passive Immunization: New Weapons in the Arsenal, Trends Microbiol., 25 (2017), 954-956.
[11]	N. Seddiki, Y. Levy Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies, Curr. Opin. HIV AIDS., 13 (2018), 119-127.
[12]	A. L. Gill, S. A. Green, S. Abdullah, C. L. Saout, S. Pittaluga, H. Chen, et al., Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients, AIDS., 30 (2016), 2487-2493.
[13]	J. Arthos, C. Cicala, E. Martinelli, K. Macleod, D. Van Ryk, D. Wei, et al., HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells, Nat. Immunol., 9 (2008), 301-309.
[14]	K. A. O'Connell, J. R. Bailey, J. N. Blankson, Elucidating the elite: mechanisms of control in HIV-1 infection, Trends Pharmacol. Sci., 30 (2009), 631-637.
[15]	E. S. Rosenberg, M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge, et al., Immune control of HIV-1 after early treatment of acute infection, Nature, 407 (2000), 523-526.
[16]	S. Liu, X. Lu, Y. Chen, B. Li, A delayed HIV-1 model with virus waning term, Math. Biosci. Eng., 13 (2016), 135-157.
[17]	N. L. Komarova, E. Barnes, P. Klenerman, D. Wodarz, Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success, Proc. Natl. Acad. Sci. USA, 100 (2003), 1855-1860.
[18]	D. D. Richman, D. Havlir, J. Corbeil, D. Looney, D. Pauletti, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J. Virol., 68 (1994), 1660-1666.
[19]	D. R. Bangsberg, F. M. Hecht, E. D. Charlebois, A. R. Zolopa, M. Holodniy, L. Sheiner, et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population, AIDS., 14 (2000), 357-366.
[20]	B. J. Epstein, Drug Resistance among Patients Recently Infected with HIV, N. Engl. J. Med., 347 (2002), 1889-1890.
[21]	M. S. Hirsch, H. F. Gunthard, J. M. Schapiro, V. Brun, S. M. Hammer, V. A. Johnson, et al., Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel, Clin. Infect. Dis., 347 (2008), 266-285.
[22]	The Wistar Institute, Interferon Decreases HIV-1 Viral Levels and Controls Virus after Stopping Antiretroviral Therapy in Patients, 2012 Conference on Retroviruses and Opportunistic Infections, 2012. Available from: https://www.positivelypositive.ca/hiv-aids-news/Interferon_decreases_HIV-1_levels.html.
[23]	M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, H. Mcdade, et al., Viral dynamics in hepatitis B virus infection, Proc. Natl. Acad. Sci. USA, 93 (1996), 4398-4402.
[24]	S. Bonhoeffer, R. M. May, G. M. Shaw, M. A. Nowak, Virus dynamics and drug therapy, Proc. Natl. Acad. Sci. USA, 94 (1997), 6971-6976.
[25]	D. Wodarz, J. P. Christensen, A. R. Thomsen, et al., The importance of lytic and nonlytic immune responses in viral infections, Trends in Immunol., 23 (2002), 194-200.
[26]	C. Bartholdy, J. P. Christensen, D. Wodarz, A. R. Thomsen, Persistent Virus Infection despite Chronic Cytotoxic T-Lymphocyte Activation in Gamma Interferon-Deficient Mice Infected with Lymphocytic Choriomeningitis Virus, J. Virol., 74 (2002), 10304-10311.
[27]	Y. Pei, C. Li, X. Liang, Optimal therapies of a virus replication model with pharmacological delays based on RTIs and PIs, J. Phys. A Math. Theor., 50 (2017), 455601.
[28]	H. Shu, L. Wang, Joint impacts of therapy duration, drug efficacy and time lag in immune expansion on immunity boosting by antiviral therapy, J. Biol. Sys., 25 (2017), 105-117.
[29]	H. Shu, L. Wang, J. Watmough, Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model, J. Math. Biol., 68 (2014), 477-503.
[30]	M. A. Nowak, C. R. Bangham, Population Dynamics of Immune Responses to Persistent Viruses, Science, 272 (1996), 74-79.
[31]	J. E. Schmitz, M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, et al., Control of Viremia in Simian Immunodeficiency Virus Infection by CD8+ Lymphocytes, Science, 283 (1999), 857-860.
[32]	C. R. Bangham, The immune response to HTLV-I, Curr. Opin. Immunol., 12 (2000), 397-402.
[33]	R. J. De Boer, A. S. Perelson, Target Cell Limited and Immune Control Models of HIV Infection: A Comparison, J. Theor. Biol., 190 (1998), 201-214.
[34]	A. Pugliese, A. Gandolfi, A Simple Model of Pathogen Immune Dynamics Including Specific and Non-Specific Immunity, Math. Biosci., 214 (2008), 73-80.
[35]	A. Fenton, J. Lello, M. B. Bonsall, Pathogen responses to host immunity: the impact of time delays and memory on the evolution of virulence, Proc. Biol. Sci., 273 (2006), 2083-2090.
[36]	N. Mcdonald, Time lags in biological models, Springer Science & Business Media, 1978.
[37]	S. Wain-Hobson, Virus Dynamics: Mathematical Principles of Immunology And Virology, Nat. Med., 410 (2001), 412-413.
[38]	L. Rong, A. S. Perelson, Modeling HIV persistence, the latent reservoir, and viral blips, J. Theor. Biol., 260 (2009), 308-331.
[39]	J. K. Hale, S. M. Verduyn Lunel, Introduction to Functional Differential Equations, Introduction to functional differential equations, 1993.
[40]	E. Beretta, Y. Kuang, Geometric stability switch criteria in delay differential systems with delay dependent parameters, SIAM J. Math. Anal., 33 (2002), 1144-1165.
[41]	K. L. Cooke, S. Busenberg, Vertically transmitted diseases, Vertically Transmitted Diseases, 1993.
[42]	B. D. Hassard, N. D. Kazarinoff, Theory and applications of Hopf bifurcation, CAMBRIDGE UNIV. PR., 1981.
[43]	S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection, AIDS., 14 (2000), 2313-2322.
[44]	L. B. Rong, A. S. Perelson, Modeling HIV persistence, the latent reservoir, and viral blips, J. Theor. Biol., 260 (2009), 308-331.
[45]	S. Wang, F. Xu, L. Rong, Bistability analysis of an HIV model with immune response, J. Biol. Sys., 25 (2017), 677-695.
[46]	B. Ingalls, M. Mincheva, M. R. Roussel, Parametric Sensitivity Analysis of Oscillatory Delay Systems with an Application to Gene Regulation, Bull. Math. Biol., 79 (2017), 1539-1563.
[47]	T. Ma, Y. Pei, C. Li, M. Zhu, Periodicity and dosage optimization of an RNAi model in eukaryotes cells, BMC Bioinformatics, 20 (2019), 340.

Reader Comments

your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)